Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34 + cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors

Journal of Biotechnology

Volumn 156, Issue 3, 2011, Pages 218-226

  Leuci, Valeria ^a,b   Mesiano, Giulia ^a   Gammaitoni, Loretta ^a   Cammarata, Cristina ^a   Capellero, Sonia ^a   Todorovic, Maja ^a   Jordaney, Noela ^a   Circosta, Paola ^a   Elia, Angela ^a   Lesnikova, Marina ^c   Georges, George E ^c,d   Piacibello, Wanda ^a   Fagioli, Franca ^b   Cignetti, Alessandro ^a   Aglietta, Massimo ^a   Sangiolo, Dario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^c USA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Hematopoietic stem cells; Lentiviral transduction; T lymphocytes; Transduction efficiency

Indexed keywords

BENEFICIAL EFFECTS; HEMATOPOIETIC STEM CELLS; LARGE SIZES; LENTIVIRAL TRANSDUCTION; LENTIVIRAL VECTOR; LOW DOSE; MEAN PERCENTAGE; PROTEASOME INHIBITORS; PROTEASOMES; T CELLS; T LYMPHOCYTES; TRANSDUCTION EFFICIENCY; TRANSIENT EXPOSURE; VIRAL PRODUCTION;

STEM CELLS; VECTORS;

BACTERIOPHAGES;

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CD34 ANTIBODY; LENTIVIRUS VECTOR; PROTEASOME;

ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, CD34; CELLS, CULTURED; FLOW CYTOMETRY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; PROTEASOME ENDOPEPTIDASE COMPLEX; REAL-TIME POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 80054095020     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2011.09.001     Document Type: Article

References (58)

1. Ailles L., Schmidt M., Santoni de Sio F.R., Glimm H., Cavalieri S., Bruno S., Piacibello W., Von Kalle C., Naldini L. Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. Mol. Ther. 2002, 6:615-626.
2. Aiuti A. Advances in gene therapy for ADA-deficient SCID. Curr. Opin. Mol. Ther. 2002, 4:515-522.
3. Aiuti A., Cattaneo F., Galimberti S., Benninghoff U., Cassani B., Callegaro L., Scaramuzza S., Andolfi G., Mirolo M., Brigida I., Tabucchi A., Carlucci F., Eibl M., Aker M., Slavin S., Al-Mousa H., Al Ghonaium A., Ferster A., Duppenthaler A., Notarangelo L., Wintergerst U., Buckley R.H., Bregni M., Marktel S., Valsecchi M.G., Rossi P., Ciceri F., Miniero R., Bordignon C., Roncarolo M.G. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 2009, 360:447-458.
4. Aiuti A., Roncarolo M.G. Ten years of gene therapy for primary immune deficiencies. Hematology Am. Soc. Hematol. Educ. Program 2009, 682-689.
5. Aiuti A., Slavin S., Aker M., Ficara F., Deola S., Mortellaro A., Morecki S., Andolfi G., Tabucchi A., Carlucci F., Marinello E., Cattaneo F., Vai S., Servida P., Miniero R., Roncarolo M.G., Bordignon C. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (New York, NY) 2002, 296:2410-2413.
6. Amendola M., Venneri M.A., Biffi A., Vigna E., Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat. Biotechnol. 2005, 23:108-116.
7. Baum C. Insertional mutagenesis in gene therapy and stem cell biology. Curr. Opin. Hematol. 2007, 14:337-342.
8. Baum C., Dullmann J., Li Z., Fehse B., Meyer J., Williams D.A., von Kalle C. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003, 101:2099-2114.
9. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (New York, NY) 1997, 276:1719-1724.
10. Buchholz C.J., Muhlebach M.D., Cichutek K. Lentiviral vectors with measles virus glycoproteins - dream team for gene transfer?. Trends Biotechnol. 2009, 27:259-265.
11. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., Veres G., Schmidt M., Kutschera I., Vidaud M., Abel U., Dal-Cortivo L., Caccavelli L., Mahlaoui N., Kiermer V., Mittelstaedt D., Bellesme C., Lahlou N., Lefrere F., Blanche S., Audit M., Payen E., Leboulch P., l'Homme B., Bougneres P., Von Kalle C., Fischer A., Cavazzana-Calvo M., Aubourg P. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (New York, NY) 2009, 326:818-823.
12. Cavalieri S., Cazzaniga S., Geuna M., Magnani Z., Bordignon C., Naldini L., Bonini C. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 2003, 102:497-505.
13. Christodoulopoulos P., Cameron L., Nakamura Y., Lemiere C., Muro S., Dugas M., Boulet L.P., Laviolette M., Olivenstein R., Hamid Q. TH2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. J. Allergy Clin. Immunol. 2001, 107:586-591.
14. Circosta P., Granziero L., Follenzi A., Vigna E., Stella S., Vallario A., Elia A.R., Gammaitoni L., Vitaggio K., Orso F., Geuna M., Sangiolo D., Todorovic M., Giachino C., Cignetti A. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR. Hum. Gene Ther. 2009, 20:1576-1588.
15. Coelen R.J., Jose D.G., May J.T. The effect of hexadimethrine bromide (polybrene) on the infection of the primate retroviruses SSV 1/SSAV 1 and BaEV. Arch. Virol. 1983, 75:307-311.
16. Cornetta K., Anderson W.F. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy. J. Virol. Methods 1989, 23:187-194.
17. Duarte R.F., Chen F.E., Lowdell M.W., Potter M.N., Lamana M.L., Prentice H.G., Madrigal J.A. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy. Gene Ther. 2002, 9:1359-1368.
18. Dull T., Zufferey R., Kelly M., Mandel R.J., Nguyen M., Trono D., Naldini L. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 1998, 72:8463-8471.
19. Follenzi A., Ailles L.E., Bakovic S., Geuna M., Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 2000, 25:217-222.
20. Frecha C., Costa C., Negre D., Gauthier E., Russell S.J., Cosset F.L., Verhoeyen E. Stable transduction of quiescent T cells without induction of cycle progression by a novel lentiviral vector pseudotyped with measles virus glycoproteins. Blood 2008, 112:4843-4852.
21. Frecha C., Levy C., Cosset F.L., Verhoeyen E. Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol. Ther. 2011, 18:1748-1757.
22. Frecha C., Levy C., Costa C., Negre D., Amirache F., Buckland R., Russell S.J., Cosset F.L., Verhoeyen E. Measles virus glycoprotein-pseudotyped lentiviral vector-mediated gene transfer into quiescent lymphocytes requires binding to both SLAM and CD46 entry receptors. J. Virol. 2011, 85:5975-5985.
23. Funke S., Schneider I.C., Glaser S., Muhlebach M.D., Moritz T., Cattaneo R., Cichutek K., Buchholz C.J. Pseudotyping lentiviral vectors with the wild-type measles virus glycoproteins improves titer and selectivity. Gene Ther. 2009, 16:700-705.
24. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (New York, NY) 2003, 302:415-419.
25. Horn P.A., Figueiredo C., Kiem H.P. Gene therapy in the transplantation of allogeneic organs and stem cells. Curr. Gene Ther. 2007, 7:458-468.
26. Johnson L.A., Morgan R.A., Dudley M.E., Cassard L., Yang J.C., Hughes M.S., Kammula U.S., Royal R.E., Sherry R.M., Wunderlich J.R., Lee C.C., Restifo N.P., Schwarz S.L., Cogdill A.P., Bishop R.J., Kim H., Brewer C.C., Rudy S.F., VanWaes C., Davis J.L., Mathur A., Ripley R.T., Nathan D.A., Laurencot C.M., Rosenberg S.A. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009, 114:535-546.
27. Kohn D.B. Lentiviral vectors ready for prime-time. Nat. Biotechnol. 2007, 25:65-66.
28. Kohn D.B. Gene therapy for childhood immunological diseases. Bone Marrow Transplant. 2008, 41:199-205.
29. Kohn D.B. Update on gene therapy for immunodeficiencies. Clin. Immunol. 2010, 135:247-254.
30. Kumar M., Keller B., Makalou N., Sutton R.E. Systematic determination of the packaging limit of lentiviral vectors. Hum. Gene Ther. 2001, 12:1893-1905.
31. Kustikova O.S., Wahlers A., Kuhlcke K., Stahle B., Zander A.R., Baum C., Fehse B. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003, 102:3934-3937.
32. Landau N.R., Page K.A., Littman D.R. Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range. J. Virol. 1991, 65:162-169.
33. Levine B.L., Homeau L.M., Boyer J., MacGregor R.R., Rebello T., Lu X., Binder G.K., Slepushkin V., Lemiale F., Mascola J.R., Bushman F.D., Dropulic B., June C.H. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 2006, 46:17372-17377.
34. Lupo-Stanghellini M.T., Provasi E., Bondanza A., Ciceri F., Bordignon C., Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum. Gene Ther. 2010, 21:241-250.
35. Maetzig T., Galla M., Brugman M.H., Loew R., Baum C., Schambach A. Mechanisms controlling titer and expression of bidirectional lentiviral and gammaretroviral vectors. Gene Ther. 2009, 17:400-411.
36. Manganini M., Serafini M., Bambacioni F., Casati C., Erba E., Follenzi A., Naldini L., Bernasconi S., Gaipa G., Rambaldi A., Biondi A., Golay J., Introna M. A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum. Gene Ther. 2002, 13:1793-1807.
37. Maruggi G., Porcellini S., Facchini G., Perna S.K., Cattoglio C., Sartori D., Ambrosi A., Schambach A., Baum C., Bonini C., Bovolenta C., Mavilio F., Recchia A. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther. 2009, 17:851-856.
38. Matrai J., Chuah M.K., VandenDriessche T. Recent advances in lentiviral vector development and applications. Mol. Ther. 2010, 18:477-490.
39. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (New York, NY) 1996, 272:263-267.
40. Neschadim A., McCart J.A., Keating A., Medin J.A. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2007, 13:1407-1416.
41. Persons D.A. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Hematology Am. Soc. Hematol. Educ. Program 2009, 690-697.
42. Piacibello W., Bruno S., Sanavio F., Droetto S., Gunetti M., Ailles L., Santoni de Sio F., Viale A., Gammaitoni L., Lombardo A., Naldini L., Aglietta M. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood 2002, 100:4391-4400.
43. Piacibello W., Sanavio F., Garetto L., Severino A., Dane A., Gammaitoni L., Aglietta M. Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation. Leukemia 1998, 12:718-727.
44. Piacibello W., Sanavio F., Severino A., Dane A., Gammaitoni L., Fagioli F., Perissinotto E., Cavalloni G., Kollet O., Lapidot T., Aglietta M. Engraftment in nonobese diabetic severe combined immunodeficient mice of human CD34(+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 1999, 93:3736-3749.
45. Porter C.D., Lukacs K.V., Box G., Takeuchi Y., Collins M.K. Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J. Virol. 1998, 72:4832-4840.
46. Sandrin V., Boson B., Salmon P., Gay W., Negre D., Le Grand R., Trono D., Cosset F.L. Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 2002, 100:823-832.
47. Sangiolo D., Lesnikova M., Nash R.A., Jensen M.C., Nikitine A., Kiem H.P., Georges G.E. Lentiviral vector conferring resistance to mycophenolate mofetil and sensitivity to ganciclovir for in vivo T-cell selection. Gene Ther. 2007, 14:1549-1554.
48. Santoni de Sio F.R., Cascio P., Zingale A., Gasparini M., Naldini L. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 2006, 107:4257-4265.
49. Santoni de Sio F.R., Gritti A., Cascio P., Neri M., Sampaolesi M., Galli C., Luban J., Naldini L. Lentiviral vector gene transfer is limited by the proteasome at postentry steps in various types of stem cells. Stem Cells 2008, 26:2142-2152.
50. Seitz B., Moreira L., Baktanian E., Sanchez D., Gray B., Gordon E.M., Anderson W.F., McDonnell P.J. Retroviral vector-mediated gene transfer into keratocytes in vitro and in vivo. Am. J. Ophthalmol. 1998, 126:630-639.
51. Sirven A., Ravet E., Charneau P., Zennou V., Coulombel L., Guetard D., Pflumio F., Dubart-Kupperschmitt A. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol. Ther. 2001, 3:438-448.
52. Smith M.L., Cavenagh J.D., Lister T.A., Fitzgibbon J. Mutation of CEBPA in familial acute myeloid leukemia. N. Engl. J. Med. 2004, 351:2403-2407.
53. Swaney W.P., Sorgi F.L., Bahnson A.B., Barranger J.A. The effect of cationic liposome pretreatment and centrifugation on retrovirus-mediated gene transfer. Gene Ther. 1997, 4:1379-1386.
54. Terwilliger E.F., Godin B., Sodroski J.G., Haseltine W.A. Construction and use of a replication-competent human immunodeficiency virus (HIV-1) that expresses the chloramphenicol acetyltransferase enzyme. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:3857-3861.
55. Varela-Rohena A., Carpenito C., Perez E.E., Richardson M., Parry R.V., Milone M., Scholler J., Hao X., Mexas A., Carroll R.G., June C.H., Riley J.L. Genetic engineering of T cells for adoptive immunotherapy. Immunol. Res. 2008, 166-181.
56. Verhoeyen E., Dardalhon V., Ducrey-Rundquist O., Trono D., Taylor N., Cosset F.L. IL-7 surface-engineered lentiviral vectors promote survival and efficient gene transfer in resting primary T lymphocytes. Blood 2003, 101:2167-2174.
57. Wurm M., Schambach A., Lindemann D., Hanenberg H., Standker L., Forssmann W.G., Blasczyk R., Horn P.A. The influence of semen-derived enhancer of virus infection on the efficiency of retroviral gene transfer. J. Gene Med. 2010, 12:137-146.
58. Yang S., Rosenberg S.A., Morgan R.A. Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells. J. Immunother. 2008, 31:830-839.